Patents Assigned to Nastech Pharmaceutical Company, Inc.
-
Patent number: 7863245Abstract: Pharmaceutical compositions comprising PYY(3-36) or Neuropeptide Y (NPY), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) or Neuropeptide Y (NPY) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.Type: GrantFiled: September 19, 2008Date of Patent: January 4, 2011Assignee: Nastech Pharmaceutical Company, Inc.Inventor: Steven C. Quay
-
Publication number: 20100254945Abstract: Disclosed herein is a double stranded siRNA molecule that inhibits production of a respiratory virus, wherein each strand of said siRNA molecule is about 15 to about 50 nucleotides, and wherein one strand of said siRNA molecule comprises a nucleic acid sequence identical to a conserved site, or a variant thereof, within the nucleic acid sequence of the respiratory virus, and uses thereof.Type: ApplicationFiled: April 7, 2006Publication date: October 7, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Qing Ge, Mukesh Kumar, James Anthony McSwiggen
-
Publication number: 20100247482Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a PN159 analog or conjugate.Type: ApplicationFiled: April 23, 2008Publication date: September 30, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Kunyuan Cui, Shu-Chih Chen, Michael E. Houston, JR., Steven C. Quay
-
Publication number: 20100209487Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.Type: ApplicationFiled: October 18, 2007Publication date: August 19, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James Mcswiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20100129460Abstract: Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsKNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA Interference.Type: ApplicationFiled: October 13, 2006Publication date: May 27, 2010Applicant: Nastech Pharmaceutical Company Inc.Inventors: Roger C. Adami, Tianying Zhu, Kunyuan Cui, Michael E. Houston, JR., Lishan Chen, Yuching Chen
-
Publication number: 20100113332Abstract: What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-? (TNF-?) in the mammal.Type: ApplicationFiled: September 27, 2005Publication date: May 6, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Lishan Chen, Kunyuan Cui, Michael E. Houston, JR., Yuching Chen
-
Publication number: 20090325860Abstract: What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.Type: ApplicationFiled: April 19, 2007Publication date: December 31, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Henry R. Costantino, Annemarie Stoudt Cohen, Anthony P. Sileno
-
Publication number: 20090274658Abstract: Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject.Type: ApplicationFiled: June 8, 2009Publication date: November 5, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY, INC.Inventors: Kunyuan Cui, Shu-Chih Chen Quay, Kristine T. Fry
-
Publication number: 20090220435Abstract: Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and delivery. Permeability can be enhanced with reversibility. Compounds and components for enhanced delivery may be peptide or protein variants, conjugates, or other analog types and structures.Type: ApplicationFiled: July 27, 2006Publication date: September 3, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, Shu-Chih Chen Quay, Kunyuan Cui, Anthony P. Sileno, Paul Hickok Johnson, Michael E. Houston, Henry R. Costantino, Michael V. Templin
-
Publication number: 20090118158Abstract: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.Type: ApplicationFiled: September 19, 2008Publication date: May 7, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventor: Steven C. Quay
-
Publication number: 20090054326Abstract: Pharmaceutical formulations are described for enhancing mucosal delivery of peptide YY (PYY) to a mammal. A PYY dosage form is described that is suitable for multi-use administration. The PYY dosage form comprises a bottle containing an aqueous pharmaceutical formulation and an actuator effective intranasal administration of the formulation. The formulation comprises a therapeutically effective amount of PYY, a buffer to control pH, a water-miscible polar organic solvent and a chelating agent for cations. The PYY dosage form exhibits at least 90% PYY recovery after storage as used for greater than about five days.Type: ApplicationFiled: July 10, 2006Publication date: February 26, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Henry R. Costantino, Mary S. Kleppe, Annemarie S. Cohen, Anthony P. Sileno
-
Publication number: 20090042790Abstract: What is described is a biological agent, comprised of a biologically active protein, or a fragment or a mimetic thereof, conjugated to at least one poly(alkylene oxide) chain having a size less than about 20 kDa, pharmaceutical formulations for intranasal delivery of said biological agent, or uses of said biological agent in the manufacture of said pharmaceutical formulation for administering said biological agent to a mammal.Type: ApplicationFiled: June 13, 2006Publication date: February 12, 2009Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Henry R. Costantino, Mary S. Kleppe, Ching-Yuan Li
-
Publication number: 20080317839Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.Type: ApplicationFiled: May 2, 2008Publication date: December 25, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, Michael Houston, JR., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Gallagher Prieve, Kathy Lynn Fosnaugh, Shaguna Seth
-
Publication number: 20080318861Abstract: What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-?-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5° C.Type: ApplicationFiled: December 7, 2006Publication date: December 25, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, Henry R. Costantino, Alexis Kays Leonard
-
Publication number: 20080318837Abstract: What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.Type: ApplicationFiled: December 1, 2006Publication date: December 25, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, Henry R. Costantino, Michael V. Templin, Alexis Kays Leonard, Mary S. Kleppe, Joshua O. Sestak
-
Publication number: 20080299659Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ApoB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ApoB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ApoB gene in a cell or in a subject to treat an ApoB-related disease.Type: ApplicationFiled: February 28, 2008Publication date: December 4, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20080293136Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing AKT gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an AKT mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an AKT gene in a cell or in a subject to treat an AKT-related disease.Type: ApplicationFiled: February 28, 2008Publication date: November 27, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20080286866Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing VEGFA, VEGFB, VEGFC, FIGF, or PGF gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a VEGF mRNA. In addition, the meroduplex may have at least one 5-methyluridine, locked nucleic acid, 2?-O-methyl, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a VEGF gene in a cell or in a subject to treat a VEGF-related disease.Type: ApplicationFiled: February 28, 2008Publication date: November 20, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20080287383Abstract: The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.Type: ApplicationFiled: February 28, 2008Publication date: November 20, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
-
Publication number: 20080261304Abstract: A double-stranded RNA, preferably a small, interfering (si)RNA or a siHybrid, to which cholesterol moieties are linked.Type: ApplicationFiled: January 11, 2008Publication date: October 23, 2008Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Mohammad Ahmadian, Kunyuan Cui, Lishan Chen, Shu-Chih Chen, Michael E. Houston